FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156081141> ?p ?o ?g. }

• W2156081141 endingPage "41" @default.
• W2156081141 startingPage "1837" @default.
• W2156081141 abstract "Several trials show that tumor markers at primary diagnosis of cancer have prognostic relevance and can predict dissemination of the disease. While MUC-1 markers are frequently used to monitor treatment efficacy in metastatic breast cancer, their role at primary diagnosis or during follow-up remains unclear. This translational research project within the SUCCESS trial evaluates the role of the tumor marker CA 27.29 before and after adjuvant chemotherapy, as well as after two and then five years in patients with early breast cancer.The SUCCESS trial compared FEC (500/100/500)-docetaxel (100) vs. FEC (500/100/500)-docetaxel/gemcitabine (75/2000) and two vs. five years of zoledronate treatment in node-positive and high-risk node-negative patients with primary breast cancer. CA 27.29 was measured before chemotherapy in 2669 patients with the reagent ST AIA-PACK CA 27.29 for AIA-600II-Analyzer (Tosoh Bioscience, Belgium). Results of CA 27.29 above 31 U/ml were regarded as positive.7.6% of patients had elevated marker levels after the completion of primary surgical treatment but before initiation of chemotherapy (n=202, mean 19, range 3-410 U/ml). No correlation between nodal status (p=0.55), grading (p=0.85), hormonal status (p=0.21), HER2/neu status on the primary tumor (p=0.58) and CA 27.29 was shown. However, larger tumor size (p=0.02), lobular histology (p<0.0001), older age (p<0.001) and postmenopausal hormone status before the start of treatment (p=0.006) were significantly associated with higher CA 27.29 levels.These data indicate a close relationship between CA 27.29 and tumor mass persisting even several weeks after surgery, but also identify potential confounding factors that should be considered in interpreting tumor marker results. Further follow-up of the SUCCESS trial will clarify whether CA 27.29 measured after surgery but before the start of systemic treatment is prognostically relevant and whether it is a useful marker for treatment monitoring in the adjuvant setting." @default.
• W2156081141 created "2016-06-24" @default.
• W2156081141 creator A5006963351 @default.
• W2156081141 creator A5008649645 @default.
• W2156081141 creator A5010293363 @default.
• W2156081141 creator A5039816488 @default.
• W2156081141 creator A5044421523 @default.
• W2156081141 creator A5044467977 @default.
• W2156081141 creator A5045891981 @default.
• W2156081141 creator A5047757604 @default.
• W2156081141 creator A5054111858 @default.
• W2156081141 creator A5059327156 @default.
• W2156081141 creator A5072762948 @default.
• W2156081141 creator A5087227508 @default.
• W2156081141 creator A5089392438 @default.
• W2156081141 date "2010-05-01" @default.
• W2156081141 modified "2023-09-23" @default.
• W2156081141 title "Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment." @default.
• W2156081141 cites W101431415 @default.
• W2156081141 cites W126331337 @default.
• W2156081141 cites W1499769321 @default.
• W2156081141 cites W1826672661 @default.
• W2156081141 cites W1942484486 @default.
• W2156081141 cites W1981646564 @default.
• W2156081141 cites W2006294663 @default.
• W2156081141 cites W2007695310 @default.
• W2156081141 cites W2019209226 @default.
• W2156081141 cites W2024651858 @default.
• W2156081141 cites W2025574132 @default.
• W2156081141 cites W2035401398 @default.
• W2156081141 cites W2065236043 @default.
• W2156081141 cites W2091221538 @default.
• W2156081141 cites W2117305280 @default.
• W2156081141 cites W2120628328 @default.
• W2156081141 cites W2129329953 @default.
• W2156081141 cites W2132434084 @default.
• W2156081141 cites W2146421261 @default.
• W2156081141 cites W2172167537 @default.
• W2156081141 cites W2406291730 @default.
• W2156081141 cites W2472057819 @default.
• W2156081141 cites W254716823 @default.
• W2156081141 cites W49105830 @default.
• W2156081141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20592389" @default.
• W2156081141 hasPublicationYear "2010" @default.
• W2156081141 type Work @default.
• W2156081141 sameAs 2156081141 @default.
• W2156081141 citedByCount "5" @default.
• W2156081141 countsByYear W21560811412012 @default.
• W2156081141 countsByYear W21560811412016 @default.
• W2156081141 countsByYear W21560811412017 @default.
• W2156081141 countsByYear W21560811412022 @default.
• W2156081141 crossrefType "journal-article" @default.
• W2156081141 hasAuthorship W2156081141A5006963351 @default.
• W2156081141 hasAuthorship W2156081141A5008649645 @default.
• W2156081141 hasAuthorship W2156081141A5010293363 @default.
• W2156081141 hasAuthorship W2156081141A5039816488 @default.
• W2156081141 hasAuthorship W2156081141A5044421523 @default.
• W2156081141 hasAuthorship W2156081141A5044467977 @default.
• W2156081141 hasAuthorship W2156081141A5045891981 @default.
• W2156081141 hasAuthorship W2156081141A5047757604 @default.
• W2156081141 hasAuthorship W2156081141A5054111858 @default.
• W2156081141 hasAuthorship W2156081141A5059327156 @default.
• W2156081141 hasAuthorship W2156081141A5072762948 @default.
• W2156081141 hasAuthorship W2156081141A5087227508 @default.
• W2156081141 hasAuthorship W2156081141A5089392438 @default.
• W2156081141 hasConcept C111683008 @default.
• W2156081141 hasConcept C118646709 @default.
• W2156081141 hasConcept C121608353 @default.
• W2156081141 hasConcept C126322002 @default.
• W2156081141 hasConcept C127413603 @default.
• W2156081141 hasConcept C143998085 @default.
• W2156081141 hasConcept C147176958 @default.
• W2156081141 hasConcept C2776694085 @default.
• W2156081141 hasConcept C2777286243 @default.
• W2156081141 hasConcept C2779013556 @default.
• W2156081141 hasConcept C2780258809 @default.
• W2156081141 hasConcept C2780283643 @default.
• W2156081141 hasConcept C2781190966 @default.
• W2156081141 hasConcept C530470458 @default.
• W2156081141 hasConcept C71924100 @default.
• W2156081141 hasConcept C90924648 @default.
• W2156081141 hasConceptScore W2156081141C111683008 @default.
• W2156081141 hasConceptScore W2156081141C118646709 @default.
• W2156081141 hasConceptScore W2156081141C121608353 @default.
• W2156081141 hasConceptScore W2156081141C126322002 @default.
• W2156081141 hasConceptScore W2156081141C127413603 @default.
• W2156081141 hasConceptScore W2156081141C143998085 @default.
• W2156081141 hasConceptScore W2156081141C147176958 @default.
• W2156081141 hasConceptScore W2156081141C2776694085 @default.
• W2156081141 hasConceptScore W2156081141C2777286243 @default.
• W2156081141 hasConceptScore W2156081141C2779013556 @default.
• W2156081141 hasConceptScore W2156081141C2780258809 @default.
• W2156081141 hasConceptScore W2156081141C2780283643 @default.
• W2156081141 hasConceptScore W2156081141C2781190966 @default.
• W2156081141 hasConceptScore W2156081141C530470458 @default.
• W2156081141 hasConceptScore W2156081141C71924100 @default.
• W2156081141 hasConceptScore W2156081141C90924648 @default.
• W2156081141 hasIssue "5" @default.

• next